Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.

Also called NCT04892199

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (planned count) (from the registry)
Sponsor
Anders Fink-Jensen, MD, DMSci (from the registry)
Registry
  • NCT NCT04892199
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04892199. Randomized; triple masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2026-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Condition
Metabolic Disturbance
Condition
Schizophrenia
Condition
Clozapine
Condition
GLP-1
Condition
Olanzapine
Intervention (Drug)
Semaglutide, 1.34 mg/mL
Intervention (Drug)
Semaglutide-placebo
Lead sponsor
Anders Fink-Jensen, MD, DMSci (class: other)

Record details

Record id
cardio:ct-nct04892199
Content hash
49963590f4085425bc6823592793353581e559c466898ec490201500dd68c758